跳至主要内容
临床试验/ChiCTR2000031929
ChiCTR2000031929已完成4 期

Comparison of efficacy of dermatological 0.1% tacrolimus in treatment on vernal keratoconjunctivitis

No funding1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2019年7月1日最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
50
试验地点
1
主要终点
Symptoms

研究概览

简要总结

Tacrolimus has been used in different concentrations for ophthalmic use. It is used in 0.1 % as well as in 0.03% concentrations. Some studies claim it is more effective in 0.1 % concentration. In most studies tacrolimus is studied in bid dose, we intend to check its efficacy in HS dose.

研究设计

研究类型
Interventional
主要目的
单臂
盲法
N/a

入排标准

年龄范围
7 至 14(—)
性别
All

入选标准

  • were all the pediatric patients of severe VKC, unmanageable with conventional treatment (anti-histamines/mast cell stabilizers/NSAIDS/steroids) or patients showing recurrence after discontinuation of steroids or having steroid-induced complications.

排除标准

  • were any coexisting ocular disorders such as conjunctival or corneal diseases, ocular infections, uveitis, Stevens Johnson syndrome, contact lens usage, history of ocular surgery. Informed consent was taken and all the patients were explained about the study.

研究组 & 干预措施

Case series

topical application of tacrolimus in conjunctival fornix at night

结局指标

主要结局

Symptoms

Conjunctival Hyperemia

Papillae size

Tranta dots

SPK grade

次要结局

未报告次要终点

研究者

发起方
No funding

研究点 (1)

Loading locations...

相似试验